Cardioverter DefIbriIlator PlacEMent for priMary Prevention of Sudden cArdiac Death in Patients Older Than 70 Years

Recruiting now · Not applicable

Conditions studied: Heart Failure, Primary Prevention of Sudden Cardiac Death, Implantable Cardioverter Defibrillator

In brief

The primary objective of DILEMMA study is to assess whether the "heart failure optimal therapy alone (HFOT)" strategy is non inferior to the "HFOT+ICD" strategy in terms of overall survival 48 months after randomization, in patients ≥ 70 years with an ICD indication for primary prevention of SCD whether there is an indication for cardiac resynchronization therapy or not.

Key facts

Study ID

NCT05373940

Run by

Assistance Publique - Hôpitaux de Paris

People needed

730

Starts

2022-06-29

Expected to finish

2030-05-31

Last updated by the study team

2026-03-24

Who can join

Age: 70 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ≥70 years old,
• Left ventricular ejection fraction ≤ 35%, assessed by echocardiography, single-photon emission computed tomography and radionuclide ventriculography and/or cardiac magnetic resonance (CMR) (assessed at inclusion or within the 6 weeks prior to inclusion).
• NYHA class II or III
• Heart failure HFOT ≥ 3 months (Possible exceptions : possibility of including patients who do not tolerate the maximum dose or who do not tolerate all four therapeutic classes, as well as the possibility of not waiting for three months when one of the classes is discontinued or when dosage adjustments are made due to poor tolerance ...)
• Providing informed consent
• Affiliated to a French Health Insurance system.

You may not qualify if…

• Enrolled in or planning to enroll in a conflicting interventional trial (trial evaluating the interest of ICD or modifying HFOT outside the last ESC Guidelines)
• Prior unstable sustained ventricular arrhythmia requiring external cardioversion
• Myocardial infarction within the 40 days
• Coronary artery intervention (catheter or surgical) within 90 days
• History of syncope in the previous 6 months
• Advanced cerebrovascular disease (cerebrovascular disease with functional repercussions or effect on the patient's autonomy)
• Cognitive impairment leading to the incapacity of consent
• Any disease other than cardiac disease (e.g. cancer, uremia, liver failure), associated with a likelihood of survival less than 1 year.
• Patient under tutorship, curatorship, or legal safeguard
• Persons deprived of their liberty by judicial or administrative decision (prisoner)

Where it is running

• Centre Hospitalier d'Aix en provence — Aix-en-Provence, France (enrolling)
• CHU Amiens-Picardie-Site sud — Amiens, France (enrolling)
• CHU Brest - Hôpital La Cavale Blanche — Brest, France (enrolling)
• HôpitalHenri Mondor — Créteil, France (enrolling)
• CHU Grenoble Alpes — La Tronche, France (enrolling)
• Groupement d'Hôpitaux de l'Institut Catholique de Lille — Lomme, France (enrolling)
• Hôpital de La Timone — Marseille, France (enrolling)
• Hôpital de Brabois — Nancy, France (enrolling)
• CHU de Nantes — Nantes, France (enrolling)
• Hôpital européen Georges Pompidou — Paris, France (enrolling)
• Hôpital Pitié-Salpétrière — Paris, France (enrolling)
• Hôpital Bichat - Claude Bernard — Paris, France (enrolling)
• CHU Poitiers — Poitiers, France (enrolling)
• Hôpital Pontchaillou — Rennes, France (enrolling)
• CHU de Rouen — Rouen, France (enrolling)
• Centre Cardiologique du Nord — Saint-Denis, France (enrolling)
• CHU Strasbourg — Strasbourg, France (enrolling)
• Clinique Pasteur — Toulouse, France (enrolling)
• Hôpital Trousseau — Tours, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.